In which remission and minimal residual disease setting is blinatumomab (Blincyto) indicated for adults with Philadelphia chromosome-negative, CD19-positive B-cell precursor ALL?

Blinatumomab (Blincyto) is indicated as monotherapy for adults with Philadelphia chromosome-negative, CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) ≥0.1%.